Immune Design (NASDAQ:IMDZ) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03, Fidelity Earnings reports. Immune Design had a negative net margin of 2,409.84% and a negative return on equity of 41.43%. The company had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.75 million.
Shares of NASDAQ IMDZ traded down $0.01 during midday trading on Thursday, reaching $1.51. 6,922 shares of the stock were exchanged, compared to its average volume of 977,827. The stock has a market capitalization of $71.77 million, a price-to-earnings ratio of -0.86 and a beta of 2.54. Immune Design has a twelve month low of $1.29 and a twelve month high of $5.05.
A number of equities analysts have issued reports on the stock. HC Wainwright set a $8.00 price target on shares of Immune Design and gave the stock a “buy” rating in a research report on Wednesday. Zacks Investment Research raised shares of Immune Design from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Tuesday, October 16th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Immune Design in a research note on Friday, October 12th. Finally, Leerink Swann cut shares of Immune Design from an “outperform” rating to a “market perform” rating in a research note on Friday, October 12th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $7.25.
ILLEGAL ACTIVITY NOTICE: This piece was first published by WKRB News and is the property of of WKRB News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.wkrb13.com/2018/11/09/immune-design-imdz-announces-earnings-results.html.
Immune Design Company Profile
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.